.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Alessandra Ferrajoli, MD

Articles

Dr Ferrajoli on Shared Decision-Making During BTK Inhibitor Selection in Hematologic Malignancies

April 15th 2024

Alessandra Ferrajoli, MD, discusses the importance of shared decision-making when considering the use of BTK inhibitors in hematologic malignancies.

Dr Ferrajoli on the Incidence of Hypertension in Patients With CLL Receiving Acalabrutinib

January 5th 2024

Alessandra Ferrajoli, MD, discusses the rationale for, and findings from, a cumulative review of hypertension in patients with chronic lymphocytic leukemia and other hematologic malignancies who received acalabrutinib.

Dr. Ferrajoli on the Benefits and Limitations of Frontline Fixed-Duration Therapy in CLL

September 15th 2023

Alessandra Ferrajoli, MD, discusses the benefits and limitations of utilizing fixed-duration therapy with monoclonal antibodies in the frontline setting for patients with chronic lymphocytic leukemia.

Dr. Ferrajoli on Remaining Challenges in Treatment of CLL

November 2nd 2016

Alessandra Ferrajoli, MD, a professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses the challenges that still remain in patients with chronic lymphocytic leukemia.

Dr. Ferrajoli on Treatment of Elderly Patients With CLL

October 22nd 2015

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses treatment options for elderly patients with chronic lymphocytic leukemia.

Dr. Ferrajoli on Managing CLL in Elderly Patients

April 15th 2014

Alessandra Ferrajoli, MD, from The University of Texas MD Anderson Cancer Center, discusses managing chronic lymphocytic leukemia (CLL) in elderly patients.

Dr. Ferrajoli on Individualized Treatment of CLL

March 21st 2014

Alessandra Ferrajoli, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses individualizing the treatment of chronic lymphocytic leukemia (CLL).

Dr. Ferrajoli on the FDA Approval of Ibrutinib in CLL

February 17th 2014

Alessandra Ferrajoli, MD, discusses the recent approval of ibrutinib for patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy.